ArticleSubstance abuse treatment, prevention, and policy2026
Kava (Piper methysticum) consumption patterns and conceptualizations: results from an online survey.
Article in Substance abuse treatment, prevention, and policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Kava (Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
background'Kava,' or 'kava kava,' (Piper methysticum) is a psychoactive plant indigenous to the Pacific Islands. Historical consumption is reported to provide anxiolytic and sedating effects. In regions where kava is native, it has been used in religious and cultural practices, as well as for medicinal purposes. The mechanisms by which kavalactones - the best studied psychoactive constituent of kava - may mediate pharmacological effects include enhancing the GABA
methodsBetween December-July 2024, an anonymous online survey on legal psychoactive products was conducted using convenience sampling. Eligible individuals had to be ≥ 18 years old and endorse lifetime use of kratom, kava, tianeptine, and/or akuamma seed.
resultsOf the 368 participants, almost half (n = 180, 48.9%) had used kava during their lifetime. Those who reported lifetime use of kava were younger on average (p = 0.001), more racially diverse (p = 0.041), and had a higher proportion of being employed or in school (p = 0.012) than those where did not use kava in their lifetime. Kava was purchased online (40.6%) or in ethnobotanical tea bars (31.7%). Many reported infrequent consumption (average = 4.4 months/year and 9.1 days/30 days). Lifetime use of alcohol, kratom, and cannabis was common. Approximately one-third of participants had consumed kava more than 100 times, with commonly reported perceived effects from kava experienced in the minutes and hours after consumption included reduced general anxiety (33.7%), improved mood (32.9%), reduced social anxiety (25.5%), and sedation (23.4%). Most respondents had favorable conceptualizations of kava, with only 11.7% characterizing that kava alone as habit-forming. Many (51.7%) conceptualized kava as an alcohol replacement with 18.3% and 16.7% using kava as a short- and/or long-term substitute for alcohol, respectively.
conclusionsKava use practices are diverse, though perceived kava effects appear mostly mild. The proliferation and diversification of kava products pre-mixed with other psychoactive botanicals requires study as the benefit-risk profile may change. Clinicians should be aware of kava use for harm-reduction and other purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.